|Year : 2014 | Volume
| Issue : 4 | Page : 450-452
Susceptibility profile of Gram-negative bacteremic isolates to beta lactam-beta lactamase inhibitor agents in comparison to other antibiotics
K Ghafur Abdul1, PR Vidyalakshmi1, VA Jayalakshmi2, I Poojary2
1 Department of Infectious Diseases, Apollo Specilaity Hospitals, Chennai, Tamil Nadu, India
2 Department of Microbiology, Apollo Specilaity Hospitals, Chennai, Tamil Nadu, India
|Date of Web Publication||1-Feb-2016|
K Ghafur Abdul
Department of Infectious Diseases, Apollo Specilaity Hospitals, Chennai, Tamil Nadu
Source of Support: None, Conflict of Interest: None
Background: Comprehensive understanding about the local antibiogram is an essential requirement for preparation of hospital or unit based antibiotic policy. Bacteremic isolates are the most useful ones for this purpose, representing invasive disease. Objective: To analyze susceptibility pattern of bacteremic Gram-negative isolates in our center, to various antibiotics, including beta lactam-beta lactamase inhibitor (BL-BLI) agents and carbapenem. Materials And Methods: This is a retrospective study done in Apollo Specialty Hospital, a tertiary care oncology center in South India. The susceptibility of Escherichia coli, Klebsiella, Acinetobacter and Pseudomonas blood culture isolates, identified between January 2013 and June 2014 to various antibiotics were analyzed. Results: A total of 231-Gram-negative bacteremic isolates were analyzed. ESBL rate among E. coli isolates was 82.7% (67 out of 81) and 74.3% (58 out of 78) in Klebsiella. Carbapenem (imipenem) susceptibility rate in E. coli was 76.5%, Klebsiella 58.9%, Acinetobacter 32% and Pseudomonas 77.2%. Colistin susceptibility in E. coli was 96.2%, Klebsiella 93.5%, Acinetobacter 92.8% and Pseudomonas 97.7%. Difference in the susceptibility of Enterobacteriaceae to BL-BLI agents (especially cefepime-tazobactam) and carbapenem were minimal. In nonfermenters, BL-BLI susceptibility was better than that of carbapenem. Conclusion: Findings of the study make a strong argument for using BL-BLI agents and sparing carbapenem to curtail the spiraling scenario of carbapenem resistance.
Keywords: Bacteremia, beta lactam-beta lactamase inhibitor, carbapenem spareres, India, oncology center
|How to cite this article:|
Abdul K G, Vidyalakshmi P R, Jayalakshmi V A, Poojary I. Susceptibility profile of Gram-negative bacteremic isolates to beta lactam-beta lactamase inhibitor agents in comparison to other antibiotics. Indian J Cancer 2014;51:450-2
|How to cite this URL:|
Abdul K G, Vidyalakshmi P R, Jayalakshmi V A, Poojary I. Susceptibility profile of Gram-negative bacteremic isolates to beta lactam-beta lactamase inhibitor agents in comparison to other antibiotics. Indian J Cancer [serial online] 2014 [cited 2019 Dec 8];51:450-2. Available from: http://www.indianjcancer.com/text.asp?2014/51/4/450/175361
| » Introduction|| |
Increasing antimicrobial resistance is a serious regional and global threat.  Immunocompromised patients, especially cancer and transplant patients are the most vulnerable targets to this dangerous scenario.  Carbapenem, the most potent group of antibiotics available in the armamentarium has started losing its sharpness and accuracy due to increasing resistance amongst Enterobacteriaceae and nonfermenter isolates. This scenario has serious implications in oncology patients, especially in the ones with neutropenia. , In nononcology practice, restricted usage of carbapenem, to those patients with severe sepsis is recommended as a strategy to curtail the escalating trend of carbapenem resistance. This strategy may not always be feasible in oncology patients, where there can be a low threshold in initiating administration of this molecule. In the era of increasing carbapenem resistance, reducing their usage by exploring alternative options could be an intelligent approach. , Beta lactam-beta lactamase inhibitors (BL-BLI) have withstood the test of time by retaining sensitivity against most Gram-negative bacteria. BL-BLI agents have been found useful in managing neutropenic sepsis even in India, a country with high Gram-negative resistance rate. ,, We analyzed susceptibility of bacteremic Gram-negative isolates in our center to various antibiotics, including BL-BLI agents and carbapenem.
| » Materials and Methods|| |
This is a retrospective study done in Apollo Specialty Hospital, a tertiary care oncology center in South India. The susceptibility of E. coli, Klebsiella, Acinetobacter and Pseudomonas blood culture isolates, identified between January 2013 and June 2014 to various antibiotics including ceftriaxone, cefoperazone-sulbactam (CS), piperacillin-tazobactam (PTZ), cefepime-tazobactam (CT), ciprofloxacin, colistin, tigecyline, aminoglycosides, cotrimoxazole and chloramphenicol were analyzed. Identification of the isolates and susceptibility testing were done using Vitek 2 compact autoanalyzer. Colistin susceptibility was done using Vitek 2 compact for all isolates and if found resistant, rechecked using E test. Pseudomonas isolates were considered to be resistant to colistin if the MIC is >8 and Acinetobacter if MIC >4. There is no available colistin breakpoint for Enterobacteriaceae as per CLSI guideline, so EUCAST breakpoints were followed (S ≤2; R >2). , Breakpoints for CS and cefepime/tazobactam are not elucidated in CLSI guideline. Hence, the breakpoints of cefoperazone and cefepime were applied for cefoperazone/sulbactam and cefepime/tazobactam, respectively.
| » Results|| |
A total of 231 gram negative bacteremic isolates were analyzed [Table 1]. ESBL rate among Escherichia coli isolates was 82.7% (67 out of 81) and 74.3% (58 out of 78) in Klebsiella. Carbapenem (imipenem) susceptibility rate in E. coli was 76.5%, Klebsiella 58.9%, Acinetobacter 32% and Pseudomonas 77.2%. CT and carbapenam sensitivities were similar amongst ESBL E. coli isolates (both 76.5%), with good sensitivity to aminoglycosides (74%) and chloramphenicol (88.8%). Klebsiella isolates also had comparable susceptibility to carbapenem and CT (58.9 and 55% respectively). CT had a better sensitivity than CS and PTZ in E. coli and Klebsiella isolates. Out of the 44 Pseudomonas isolates 90% showed susceptibility to PTZ. Susceptibility to CT (88.6%) was better than imipenem (77.2%). Of 28 Acinetobacter isolates, there was a higher sensitivity to CT (39.2%) than imipenem (32%). Though ciprofloxacin susceptibility was very low in E. coli (25.9%), Klebsiella (39.7%) and Acinetobacter (32%), Pseudomonas retained excellent sensitivity (81.8%). Colistin susceptibility in E. coli was 96.2%, Klebsiella 93.5%, Acinetobacter 92.8% and Pseudomonas 97.7%.
| » Discussion|| |
As reported from most centers in the region and across the globe, high rates of antimicrobial resistance amongst Gram-negative bacteria, is a serious problem in our center as well. ,, Our hospital has a well-established department of Infectious diseases and Infection control with published evidence of the success of antibiotic stewardship. We have a strict policy on the use of high-end antibiotics including carbapenem and on antibiotic usage for perioperative surgical prophylaxis. ,,, Our published data reveals relatively stable, but high rate of carbapenem resistance in Acinetobacter and a very encouraging trend of increasing susceptibility among Pseudomonas isolates.  At the same time, carbapenem resistance among the Enterobacteriaceae has been steadily increasing over the last few years, in tune with the trend in most centers in the country. 
The current data reveals an interesting picture of a very comparable susceptibility of Enterobacteriaceae to BL-BLI agents and carbapenem. In nonfermenters, BL-BLI susceptibility is, in fact, better than that of carbapenem. Of all BL-BLI agents tested, CT was the most susceptible agent in E. coli, Klebsiella and Acinetobacter though all BL-BLI agents performed well against Pseudomonas.
The concern on the impact of "inoculum effect" in patients with severe sepsis with possible high bacteria load has been an important factor hindering clinicians from using BL-BLI agents in these patients. Emerging evidence on the effectiveness of these agents in bacteremic and even in neutropenic patients could be a very encouraging trend, helping clinicians to choose BL-BLI agents rather than being overtly dependent on carbapenem antibiotics. ,,, A clinical study from our own center had shown similar mortality and outcomes among the carbapenem and BL-BLI treated groups, in neutropenics and nonneutropenic population. ,, Published data from our center had also highlighted high CT in-vitro susceptibility and good in-vivo performance. ,
Emerging problem of colistin resistance is a serious cause for anxiety, similar to reports from many other centers. ,,,,,, Fosfomycin sensitivity was not done, and so these colistin resistant isolates are better referred to as "possible Pan drug-resistant" isolates.  We have recently published clinical profile of a series of patients with possible pan drug-resistant bacterial infections. 
| » Conclusion|| |
The high rate of Enterobacteriaceae resistance to carbapenem is a serious concern. At the same time reducing carbapenem resistance in Pseudomonas is encouraging. The study reveals similar susceptibility of BL-BLI agents and carbapenem in Enterobacteriaceae and better susceptibility in nonfermenters. Compelling laboratory data on the superior susceptibility and available clinical data in literature on equivalence make a strong argument for using BL-BLI agents and sparing carbapenem to curtail the spiraling and catastrophic scenario of carbapenem resistance.
| » References|| |
Abdul Ghafur K. An obituary - On the death of antibiotics! J Assoc Physicians India 2010;58:143-4.
Arias CA, Murray BE. Antibiotic-resistant bugs in the 21 st
century - A clinical super-challenge. N Engl J Med 2009;360:439-43.
Ghafur A. A Call to action: For the attention of oncologists! South Asian J Cancer 2012;1:48-9.
Bia FJ. A call to action by Dr. Abdul Ghafur, Apollo Hospital, Chennai. South Asian J Cancer 2012;1:48.
Ghafur A, Vidyalakshmi PR, Priyadarshini K, Thirunarayanan MA. Fosfomycin-Promising Option in the Era of NDM-1-The First In vitro
Data from India. ICAAC, Denver No 911; 2013.
Deshpande P, Rodrigues C, Shetty A, Kapadia F, Hedge A, Soman R. New Delhi Metallo-beta lactamase (NDM-1) in Enterobacteriaceae
: Treatment options with carbapenems compromised. J Assoc Physicians India 2010;58:147-9.
Ghafur A, Tayade A, Kannaian P. Clinical profile of patients treated with cefepime/tazobactam: A new ß-lactam/ß-lactamase inhibitor combination. J Microbiol Infect Dis 2012;2:79-86.
Ghafur A, Pushparaju R, Nalini S, Rajkumar K, Sureshkumar D. Sensitivity pattern of Gram negative bacteria to the new â-lactam/â-lactamase inhibitor combination: Cefepime/tazobactam. J Microbiol Infect Dis 2012;2:5-8.
Ghosh I, Raina V, Kumar L, Sharma A, Bakhshi S, Thulkar S, et al
. Profile of infections and outcome in high-risk febrile neutropenia: Experience from a tertiary care cancer center in India. Med Oncol 2012;29:1354-60.
CLSI. Performance Standards for Antimicrobial Susceptibility Testing. USA: CLSI; 2013.
European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters Version 3.1, Valid from 2013 to 02-11.
Goel N, Wattal C, Oberoi JK, Raveendran R, Datta S, Prasad KJ. Trend analysis of antimicrobial consumption and development of resistance in non-fermenters in a tertiary care hospital in Delhi, India. J Antimicrob Chemother 2011;66:1625-30.
Ghafur A, Mathai D, Muruganathan A, Jayalal JA, Kant R, Chaudhary D, et al.
The Chennai Declaration: A roadmap to tackle the challenge of antimicrobial resistance. Indian J Cancer 2013;50:71-3.
Ghafur A. Call for global action to halt the superbug. Med J Aust 2013;198:251.
Ghafur A, Nagvekar V, Thilakavathy S, Chandra K, Gopalakrishnan R, Vidyalakshmi P, et al.
Save Antibiotics, Save lives: An Indian success story of infection control through persuasive diplomacy. Antimicrob Resist Infect Control 2012;1:29.
Ghafur A, Vidyalakshmi PR, Chandra K. Successful implementation of an infection control programme in a tertiary care oncology centre from a developing country. Geneva: ICPIC; 2013. p. 262.
Ghafur A, Vidyalakshmi PR, Ashwini T, Chandra K, Pushparaju K. Call for joint effort to tackle Gram negative resisitance. Tsunami can't be blocked with a barricade Paper no 121. ISAAR, Kuala Lumpur, 9 th
13 March, 2013.
Ghafur A, Vidyalakshmi PR, Chandra K, Anna Marie S, Bharadwaj S. Little steps towards infection control: Where there is a will, there is a way; Even in the NDM-1 Era. San Fransisco: ICAAC 2012. [Abstract K-236].
Vidyalakshmi PR, Ghafur KA, Gopalakrishnan R, Ramasubramanian V, Thirunarayanan MA. Rising Carbapenem Resistance: The Sky's the Limit! ABS117/12. Chennai: CIDSCON 2012.
Rodríguez-Baño J, Navarro MD, Retamar P, Picón E, Pascual Á, Extended-Spectrum Beta-Lactamases-Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria Group. â-Lactam/â-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum â-lactamase-producing Escherichia coli
: A post hoc analysis of prospective cohorts. Clin Infect Dis 2012;54:167-74.
Livermore DM, Hope R, Mushtaq S, Warner M. Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers. Clin Microbiol Infect 2008;14 Suppl 1:189-93.
Karaman S, Vural S, Yildirmak Y, Emecen M, Erdem E, Kebudi R. Comparison of piperacillin tazobactam and cefoperazone sulbactam monotherapy in treatment of febrile neutropenia. Pediatr Blood Cancer 2012;58:579-83.
Bodey G, Abi-Said D, Rolston K, Raad I, Whimbey E. Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients. Eur J Clin Microbiol Infect Dis 1996;15:625-34.
Ghafur A, Priyadarshini, Vidyalakshmi PR. Clinical Profile of Carbapenem Resistant Bacteraemia Among Paediatric Population-First Clinical Study From India. A-534-0002-01455 Entitled at the 31 st
Annual Meeting of the European Society for Paediatric Infectious Diseases. May 28-June 1, 2013-Milan, Italy.
Ghafur A, Kannaian P, Tayade A. Clinical study on carbapenem sensitive and carbapenem resistant bacteremia in neutropenic and non-neutropenic patients: The first series from India. Berlin: ECCMID; 2013. p. 1368.
Tayade A, Ghafur A, Priyadarshini K, Revathy R, Raja T, Easow JM. Clinical profile of Oncology patients with carbapenem resistant bacteraemia: The first case series from India. Genoa, Italy: ICHS; 2012.
Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassopoulou P, Michalopoulos A. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis 2005;5:24.
Marchaim D, Chopra T, Pogue JM, Perez F, Hujer AM, Rudin S, et al
. Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae
in metropolitan Detroit, Michigan. Antimicrob Agents Chemother 2011;55:593-9.
Taneja N, Singh G, Singh M, Sharma M. Emergence of tigecycline and colistin resistant Acinetobacter baumanii
in patients with complicated urinary tract infections in north India. Indian J Med Res 2011;133:681-4.
Mohanty S, Maurya V, Gaind R, Deb M. Phenotypic characterization and colistin susceptibilities of carbapenem-resistant of Pseudomonas aeruginosa
spp. J Infect Dev Ctries 2013;7:880-7.
Jaggi N, Sissodia P, Sharma L. Acinetobacter baumannii
isolates in a tertiary care hospital: Antimicrobial resistance and clinical significance. J Microbiol Infect Dis 2012;2:57-63.
Goel G, Hmar L, Sarkar De M, Bhattacharya S, Chandy M. Colistin-resistant Klebsiella pneumoniae
: Report of a cluster of 24 cases from a new oncology center in eastern India. Infect Control Hosp Epidemiol 2014;35:1076-7.
Shrivastava G, Bhatambare GS, Patel K. Evaluation of in vitro
sensitivity of Colistin to carbapenemase producing Gram-negative bacilli. Int Med J Sifa Univ 2014;1:31-3.
Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al.
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81.
Ghafur A, Vidyalakshmi PR, Murali A, Priyadarshini K, Thirunarayan MA. Emergence of Pan-drug resistance amongst gram-negative bacteria! The First case series from India. J Microbiol Infect Dis 2014;4:86-91.
|This article has been cited by|
||Re: “Comparison of antipseudomonal betalactams for febrile neutropenia empiric therapy: systematic review and network metaanalysis” by Horita et al.
| ||D. Averbuch,C. Orasch,M. Mikulska,D.M. Livermore,C. Viscoli,I.C. Gyssens,W.V. Kern,G. Klyasova,O. Marchetti,D. Engelhard,M. Akova,T. Calandra,C. Cordonnier |
| ||Clinical Microbiology and Infection. 2018; 24(6): 662 |
|[Pubmed] | [DOI]|